$1.1 B

ASMB Mkt cap, 20-Jul-2018
Assembly Biosciences Net income (Q1, 2018)-16.2 M
Assembly Biosciences EBIT (Q1, 2018)-16.7 M
Assembly Biosciences Cash, 31-Mar-201866.9 M

Assembly Biosciences Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

33.1 m44.2 m

General and administrative expense

12.2 m17 m

Operating expense total

45.3 m61.2 m

EBIT

(98.2 m)(24 m)(29.7 m)(45.3 m)(52.2 m)

Interest income

983.2 k

Pre tax profit

(44.9 m)(51.9 m)

Income tax expense

617.7 k9.1 m

Net Income

(111.7 m)(23.8 m)(28.5 m)(44.3 m)(42.8 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

1.1 m3.7 m3.8 m4.7 m4.6 m8.1 m7.5 m8.8 m10.6 m12.1 m14.5 m

General and administrative expense

1.4 m7.4 m3.4 m2.5 m2.5 m3.2 m2.9 m2.8 m4 m3.8 m5.7 m

Operating expense total

2.5 m11.1 m7.2 m7.2 m7.1 m11.3 m10.5 m11.7 m14.6 m15.9 m20.2 m

EBIT

(2.5 m)(11.1 m)(7.2 m)(7.2 m)(7.1 m)(11.3 m)(10.5 m)(11.7 m)(13.9 m)(13.6 m)(16.7 m)

Interest income

36.9 k35.2 k58.3 k446.4 k

Pre tax profit

(13.7 m)

Income tax expense

69.5 k

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)(13.6 m)(16.2 m)

Assembly Biosciences Balance Sheet

Annual

usdY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016FY, 2017

Cash

81.3 k14.6 m37 m20.5 m27.1 m29.1 m27.1 m28.6 m82 m

Accounts Receivable

Inventories

611.2 k

Current Assets

27.1 m29.2 m68.4 m53.6 m123.1 m

PP&E

156.4 k148.6 k214.7 k860 k

Goodwill

12.7 m12.6 m12.6 m12.6 m

Total Assets

27.1 m71.2 m133.7 m98.1 m169.3 m

Accounts Payable

2.6 m907.6 k1.4 m2.4 m2.1 m

Short-term debt

Current Liabilities

1.1 m3.4 m7.1 m13.5 m

Long-term debt

Non-Current Liabilities

11.6 m11.1 m42.7 m

Total Liabilities

15 m18.2 m56.2 m

Additional Paid-in Capital

135.8 m194.1 m283.5 m288.7 m364.5 m

Retained Earnings

(135.5 m)(164 m)(208.2 m)(251 m)

Total Equity

24.5 m58.6 m118.7 m79.9 m113.1 m

Financial Leverage

1.1 x1.2 x1.1 x1.2 x1.5 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

21.3 m17.9 m96.1 m53.5 m36.4 m20.4 m20.3 m23.8 m70.8 m39.5 m66.9 m

Accounts Receivable

1.1 m

Current Assets

21.7 m18.1 m96.3 m71.3 m66.5 m59.1 m64.1 m59.3 m92.2 m77.7 m113.2 m

PP&E

173.2 k174 k156.5 k132.2 k113.7 k128.5 k182.8 k131.9 k731.5 k

Goodwill

12.1 m12.7 m12.6 m12.6 m12.6 m12.6 m12.6 m12.6 m12.6 m12.6 m

Total Assets

21.8 m60.4 m138.3 m144.7 m139.7 m124.5 m117.2 m109.1 m134.3 m122.8 m156 m

Accounts Payable

1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m687.9 k2.4 m

Current Liabilities

1.5 m1 m2.1 m2.2 m2.7 m3.6 m5 m7.5 m11 m12 m12.2 m

Non-Current Liabilities

11.6 m11.6 m11.6 m11.6 m11.6 m55.4 m54.3 m41.5 m

Total Liabilities

13.2 m13.7 m13.8 m14.3 m15.2 m16.6 m19.1 m66.4 m66.2 m53.6 m

Additional Paid-in Capital

138.2 m176.1 m267.3 m280.6 m282 m285 m286.5 m287.5 m290.6 m292.7 m370.1 m

Retained Earnings

(118.3 m)(129.3 m)(142.7 m)(149.6 m)(156.2 m)(175 m)(185.1 m)(196.7 m)(222.2 m)(235.8 m)(267.3 m)

Total Equity

20.3 m47.2 m124.6 m130.9 m125.4 m109.3 m100.6 m90 m67.9 m56.5 m102.4 m

Financial Leverage

1.1 x1.3 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x2 x2.2 x1.5 x

Assembly Biosciences Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(19.4 m)(23.8 m)(28.5 m)(44.3 m)(42.8 m)

Depreciation and Amortization

6.2 k11 k65 k80.3 k219.2 k

Accounts Receivable

Inventories

93.1 k

Accounts Payable

(107.4 k)(2.5 m)456.1 k1 m(244.2 k)

Cash From Operating Activities

(17.8 m)(15 m)(18.7 m)(34.9 m)1.9 m

Purchases of PP&E

(150 k)(58.3 k)

Cash From Investing Activities

(6.5 k)277.4 k(64.9 m)36.2 m(15.6 m)

Cash From Financing Activities

24.4 m16.7 m81.6 m152.6 k67.2 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)(27.5 m)(16.2 m)

Depreciation and Amortization

168.1 k

Accounts Payable

2.3 m1.4 m1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m248.9 k

Cash From Operating Activities

(15.5 m)

Cash From Investing Activities

(1.1 m)

Cash From Financing Activities

1.5 m

Assembly Biosciences Ratios

USDY, 2018

Financial Leverage

1.5 x
Report incorrect company information